Do the new lipid formulations of amphotericin B really work?

Clinical Microbiology and Infection

Volumn 3, Issue 3, 1997, Pages 283-288

  Tang, Christoph M ^a   Bowler, Ian C J W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; INTRALIPID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030837524     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1997.tb00615.x     Document Type: Review

References (37)

1. Lopez Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1984; 1: 199-205.
2. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754-60.
3. Salonen J, Nikoslelainen J. Lethal infections in patients with haematological malignancies. Eur J Haematol 1993; 51: 102-8.
4. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis; review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147-201.
5. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B hpid complex therapy of experimental fungal infections in mice. Antimicrobial Agents Chemother 1991; 35: 615-21.
6. Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991; 164: 418-21.
7. Walsh TJ, Anaissie EJ, Hiemenz JW. Amphotericin B lipid complex for the treatment of severe systemic mycosis in patients with haematologic malignancies [abstract 1207]. Blood 1994; 84: 306.
8. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B complex in the treatment of 228 cases of invasive mycosis [abstract M69]. In. Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. Washington DC: American Society of Microbiology, 1994: 247.
9. Lister J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996; 56(suppl 57): 18-23.
10. Lister J. Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant of amphotericin B therapy [abstract 1209]. Blood 1994; 84: 3069.
11. Heimenz JW, Lister J, Anaissie EJ, et al. Emergency use Amphotericin B Lipid Complex (ABLC) in the treatment of invasive aspergillosis: historical control comparison with amphotericin B [abstract 3383]. Blood 1995; 86: 849a.
12. Anaissie EJ, White M, Uzun O, et al. Amphotericin B Lipid Complex (ABLC) versus amphotericin B (AmB) for the treatment of haematogenous and invasive candidiasis: a prospective, randomised multicentre trial [abstract LM21]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington DC: American Society for Microbiology, 1995: 330.
13. Janknegt R, de Marie S, Bakker Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 279-91.
14. Adler Moore JP, Chiang SM, Satorius A, et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother 1991; 28(suppl B): S63-71.
15. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994; 169: 1057-61.
16. Viviani MA, Rizzaradini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994; 22: 137-42.
17. Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994; 26: 1833.
18. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long term results of a randomized placebo-controlled trial. Transplant Proc 1995; 27: 1195-8.
19. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome) - a report on 40 cases from a single centre. Leuk Lymphoma 1992; 7(suppl): S73-7.
20. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(suppl B): S73-82.
21. Ng TT, Denning DW. Liposomal and amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155: 1093-8.
22. Kruger W, Stockschlader M, Russmann B, et al. Experience with liposomal amphotericin B in 60 patients undergoing high dose therapy and bone marrow or peripheral blood stem cell transplantation. Br J Haematol 1995; 91: 684-90.
23. Trissel LA. Amphotericin B does not mix with fat emulsion. AmJ Health Syst Pharm 1995; 52: 1463-4.
24. Kirsh R, Bugelski PJ, Poste G. Drug delivery to macrophages for the therapy of cancer and infectious diseases. Ann NY Acad Sci 1987; 507: 141-54.
25. Caillot D, Chavanet P, Casasnovas O, et al. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992; 11: 722-5.
26. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992; 30: 535-41.
27. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intrahpid in patients with haematological malignancies. J Antimicrob Chemother 1994; 33: 603-13.
28. Chavanet PY, Garry I, Charlier I, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 1992; 305: 921-5.
29. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993; 31: 161-9.
30. Sievers TM, Kubak BM, Wong-Beringer A. Safety and efficacy of Intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996; 38: 333-47.
31. Hanson HL, Stevens DA. Comparison of anrifungal activity of amphotericin deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992; 35: 486-8.
32. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. Single dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrobial Agents Chemother 1991; 35: 1029-35.
33. Bowden RA, Cays M. Phase I study of amphotericin B colloidal dispersion (ABCD: Amphocil) for the treatment of invasive fungal infection after marrow transplant [abstract 1685]. Blood 1993; 82: 425a.
34. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995; 21: 1145-53.
35. Dollery C. Therapeutic drugs, 2nd edn. Edinburgh: Churchill Livingstone, 1991: A114
36. Ringden O, Tollemar J. Liposomal amphotericin B treatment of invasive fungal infections in immunocompromised children. Mycoses 1993; 36. 187-92.
37. Zoubek A, Emminger W, Emminger-Schmidmeier W, et al. Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatr Haematol Oncol 1992; 9: 187-90.